KCM
ABBV icon

Kathmere Capital Management’s AbbVie ABBV Stock Holding History

Kathmere Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Buy
7,045
+801
+13% +$172K 0.09% 155
2026
Q1 		$1.36M Buy
6,244
+1,827
+41% +$405K 0.08% 166
2025
Q4 		$1.01M Buy
4,417
+351
+9% +$80K 0.07% 190
2025
Q3 		$941K Buy
4,066
+651
+19% +$133K 0.07% 180
2025
Q2 		$634K Buy
3,415
+91
+3% +$16.9K 0.05% 237
2025
Q1 		$696K Buy
3,324
+428
+15% +$83.2K 0.06% 189
2024
Q4 		$515K Buy
2,896
+400
+16% +$73.5K 0.05% 220
2024
Q3 		$493K Buy
2,496
+775
+45% +$145K 0.05% 208
2024
Q2 		$295K Sell
1,721
-548
-24% -$90.8K 0.03% 261
2024
Q1 		$413K Buy
2,269
+71
+3% +$12.2K 0.05% 188
2023
Q4 		$341K Sell
2,198
-801
-27% -$117K 0.04% 187
2023
Q3 		$447K Buy
2,999
+392
+15% +$57.5K 0.07% 136
2023
Q2 		$351K Sell
2,607
-1,011
-28% -$148K 0.05% 145
2023
Q1 		$577K Buy
3,618
+563
+18% +$86.1K 0.09% 105
2022
Q4 		$494K Buy
3,055
+784
+35% +$120K 0.09% 100
2022
Q3 		$305K Buy
2,271
+55
+2% +$7.89K 0.06% 121
2022
Q2 		$339K Buy
2,216
+65
+3% +$9.93K 0.06% 105
2022
Q1 		$349K Buy
2,151
+488
+29% +$70.9K 0.06% 110
2021
Q4 		$225K Buy
+1,663
New +$196K 0.04% 126
2021
Q1 		– Sell
-1,411
Closed -$151K – 135
2020
Q4 		$151K Buy
1,411
+200
+17% +$19.2K 0.03% 148
2020
Q3 		$106K Buy
+1,211
New +$114K 0.03% 173
2020
Q1 		– Sell
-2,895
Closed -$256K – 81
2019
Q4 		$256K Buy
+2,895
New +$240K 0.09% 86

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Kathmere Capital Management's ABBV Position: Q2 2026 in Review

Kathmere Capital Management increased its AbbVie (ABBV) stake by 13% in Q2 2026, buying an estimated $172K and bringing the position to 7,045 shares worth $1.77M. The position accounts for 0.09% of the portfolio, ranked #155.

Kathmere Capital Management first reported a position in ABBV in Q4 2019 and has held it in 22 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Kathmere Capital Management held 7,045 shares of AbbVie worth $1.77M as of Q2 2026.
  • Kathmere Capital Management bought 801 AbbVie shares in Q2 2026, an estimated $172K.
  • AbbVie made up 0.09% of Kathmere Capital Management's portfolio in Q2 2026, its #155 holding.
  • Kathmere Capital Management first reported a position in AbbVie in Q4 2019 and has held it in 22 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Kathmere Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.